A new study of nearly 8,800 women with early-stage breast cancer found that fewer than half -- approximately 49 percent -- completed their full regimen of hormone therapy according to the prescribed schedule. Investigators found that younger women were particularly likely to discontinue treatment. The findings underscore the need to both better understand the reasons behind such treatment non-compliance and also develop interventions to reduce it.